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Abstract 
 
Many people have the mistaken notion that, being natural, all herbs and foods are safe; this is not so. Very often, herbs 
and food may interact with medications you normally take, result in serious reactions. During the latter part of this century the 
practice of herbalism has become mainstream throughout the world. This is due remove to the recognition of the value of 
traditional medical systems in the world. Herbal medicines are mixtures of more than one active ingredient. The multitude of 
pharmacologically active compounds obviously increases the likelihood of interactions taking place. Hence, the likelihood of 
herb-drug interactions is theoretically higher than drug-drug interactions because synthetic drugs usually contain single chemical 
entity. Case reports and clinical studies have highlighted the existence of a number of clinically important interactions, although 
cause-and-effect relationships have not always been established. Herbs and drugs may interact either pharmacokinetically or 
pharmacodynamically. The predominant mechanism for this interaction is the inhibition of cytochrome P-450 3A4 in the small 
intestine; result in a significant reduction of drug presystemic metabolism. An additional mechanism is the inhibition of P-
glycoprotein, a transporter that carries drug from the enterocyte back to the gut lumen, result in a further increase in the fraction of 
drug absorbed. Some herbal products (e.g. St. John’s wort) have been shown to lower the plasma concentration (and/or the 
pharmacological effect) of a number of conventional drugs including cyclosporine, indinavir, irinotecan, nevirapine, oral 
contraceptives and digoxin.  The data available so far, concerning this interaction and its clinical implications are reviewed in this 
article. It is likely that more information regarding such interaction would crop up in the future, awareness of which is necessary 
for achieving optimal drug therapy. 
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Introduction 
 
Many medicinal herbs and pharmaceutical drugs are therapeutic at one dose and toxic at another. Interactions between 
herbs and drugs may increase or decrease the pharmacological or toxicological effects of either component. Synergistic 
therapeutic effects may complicate the dosing of long-term medications e.g. herbs traditionally used to decrease glucose 
concentrations in diabetes could theoretically precipitate hypoglycaemia if taken in combination with conventional drugs 
(Agrawal et al., 2006). Herbal medicines are ubiquitous: the dearth of reports of adverse events and interactions probably reflects 
a combination of under-reporting and the benign nature of most herbs used. Due to the increasing use of herbal and other dietary 
supplements, healthcare providers and consumers need to know whether problems arise by using these preparations in 
combination with conventional drugs (Smith et al., 2000). The use of herbal products has dramatically increased over the past 
decade, driving physicians to become educated in regard to potential herbal complications and drug interactions. From 1990 to 
1997, the market of herbal product increased by 48%, with 42% of the population using alternative treatments and spending an 
estimated $27 billion on them (Eisenberg et al., 1998). Herbal products are widely available, relatively inexpensive, and often 
make alluring but unsubstantiated claims. Herbal medicine appeals to consumers who believe that natural herbal products are 
preferable to synthetic pharmaceuticals (Kaptchuk et al., 1998). Usually herbal preparations are well thought-out more safe than 
pharmaceutical drugs although there are some potential adverse reactions from taking both together (Schultz et al., 1998).  
A relevant safety concern associated with the use of herbal medicines is the risk of interaction with prescription 
medications (Ernst et al., 2000). This issue is especially important with drugs having narrow therapeutic index such as warfarin or 
digoxin (Izzo et al., 2004). Recent examinations have indicated that as many as16% of prescription drug consumers consume 
herbal supplements. Exacerbating the problem, herbal remedies are often marketed on the Internet with misleading and unproved 
claims. Despite repeated warnings, consumers continue to equate ‘‘natural’’ with safe. As use of herbal remedies become more 
prevalent and reports of adverse effects continue to mount, there arises a need to understand better about potential complications 
by the healthcare professionals. There are numerous products currently available in the markets that have been associated with 
toxicity. The aim of this article is to highlight the clinical interactions between herbal remedies and prescribed drugs. Here we 
present information regarding different approaches used to study the interaction of herbs and drugs that involve drug metabolizing 
enzymes and transporters. Theoretical herb drug interactions which are based on in vitro experiments, animal studies and 
speculative empirical evidence can be found elsewhere (Marechal1 et al., 2008). 
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Chemicals present in herbal products 
 
This is misconception among peoples using herbal products that, herbal preparations being natural in origin are good for 
human’s health for safety point of view. There is little public awareness or appreciation of the fact that these “all natural” extracts 
are actually a combination of potentially biologically active compounds that exist in these marketed products in unknown 
quantities. The use of herbal products in the United States has skyrocketed in the past decade as a result of the patient’s pursuit of 
finding an ‘all natural’ alternative to the conventional western medicine. Marketed herbal products contain structurally diverse 
chemicals and many of which either possess inherent pharmacological activity or even show possible toxicity. Among the more 
popular herbal products Milk thistle and St. John's wort are two popular herbal products marketed to treat liver disorders and 
depression, respectively (Jacobs et al., 2002, Rodriguez et al., 2003, Chavez et al., 2006). Several clinical studies and case reports 
have demonstrated the potential benefits of St. John's wort compared with conventional therapy in the treatment of mild to 
moderate depression (Linde et al., 1996, Wheatley et al., 1997, Hussain et al., 2009). Studies conducted in vitro and in vivo have 
shown that St. John's wort constituents inhibit the reuptake of neurotransmitters linked to depression in humans (Nathan et al., 
1999). St. John's wort, an extract of the flowering portion of the plant Hypericum perforatum, is a mixture of a number of 
biologically active and complex compounds (Figure 1). At 0.3 mg per capsule, the napthodianthrone, hypericin is used as a means 
of standardization of the marketed product.  
Milk thistle [Silybum marianum (L.) (Family; Asteraceae)] extract is one of the most commonly used nontraditional 
therapies, particularly in Germany. Clinically, milk thistle is being studied as a therapy in the treatment of prostate cancer and has 
been used in the treatment of a variety of liver disorders. Milk thistle is known to contain a number of flavonolignans, compounds 
that are produced in plants by radical coupling of a flavonoid and a phenylpropanoid (Dewick et al., 1997). A mixture of these 
flavonolignans, termed silymarin, is known to be composed of mainly silybin (about 50–70%), silychristin, silydianin other 
closely related flavonolignans (Wagner et al., 1986)  (Figure 2). A standardized extract of milk thistle contains at least 70% 
silymarin (Foster et al., 1999, Schulz et al., 2001). By above data it is clear that structurally diverse chemical constituents are 
present in herbal extracts. These chemicals must be eliminated from the body either through the kidney or through the liver. 
 
Biological description of Cytochrome P450 
 
The CYP enzymes involved in drug metabolism in humans are expressed predominantly in the liver. However, it is also 
present in intestines (both large and small), lungs and brain. They are insoluble proteins, bound to the endoplasmic reticulum with 
complex mechanistic and structural features. However, the first crystal structure of mammalian CYP enzymes have recently been 
determined namely CYP2C5, CYP2B4, CYP2C9 and CYP3A4 (Paul et al., 1996, Meunier et al., 2004) and thus, much progress 
can be expected in this area in near future. It is believed that 15-20 different CYP enzymes insofar contribute to drug metabolism 
in the human liver. However, the CYP enzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 are considered most important among them 
(Werck et al., 2000, Degtyarenko et al., 1995, Guengerich et al., 2006, Guengerich et al., 1997). They have different yet 
complementary substrate specificities with ability to metabolize a vast array of xenobiotics. CYP3A4 acts on most lipophilic 
substrates and is known to metabolize more than 50% of the drugs in the liver (Munasinghe et al., 2002), whilst CYP2D6 exhibits 
a preference for positively charged molecules, usually with basic nitrogen. CYP2C9 metabolizes weakly anionic molecules, 
CYP1A2 metabolizes poly-aromatic hydrocarbons and CYP2E1 metabolizes small and soluble organics. Therefore, the CYP 
systems can metabolize almost any organic xenobiotic. Drugs can increase or decrease the activity of one or more CYP enzymes, 
which alters the rate at which the drug is degraded and cleared from the body. This can work in both ways. When a drug increases 
the activity of a CYP protein, CYP can render the drug ineffective, because it is cleared too quickly from the body. Alternatively, 
when a drug inhibits a CYP protein, CYP may not prevent the drug from accumulating to toxic levels, even to the extent of 
causing an overdose. CYP1, CYP2, CYP3 and CYP4 are most important for drug biotransformation among CYP proteins. 
CYP3A4 is the most prevalent in the body and is known to metabolize several drugs (Glue et al., 1999, Robertson et al., 2005, 
Warrington et al., 2005). 
 
Definition and classification of drug interaction 
 
Interaction is said to occur when the effect of one drug is altered by the presence of another drug(s), food or drink. 
(Stockley et al., 2002). When a therapeutic combination could lead to an unexpected change in the condition of the patient, this 
would be described as an interaction of potential clinical significance. The net effect of the combination may be synergism or 
additive effect of one or more drugs, antagonism or negative effect of one or more drugs, alteration of the effect of one or more 
drugs or the production of idiosyncratic effects (Grenier et al., 2003). A drug–drug interaction can be defined as the effect that one 
drug has on another. Drug-drug interactions can be pharmacokinetic or pharmacodynamic in nature (Nebert et al., 2002, 
Christians et al., 2005) and are not exclusive to the elderly population. Pharmacokinetics (what the body does to the drug) involve 
the effects of one drug on the absorption, distribution, metabolism, or excretion of another drug. These interactions can result in 
changes in serum drug concentrations which might alter the clinical response. The most frequent pharmacokinetic drug–drug 
interactions involve several isoenzymes of the hepatic cytochrome P450 (CYP) and drug transporters such as the P-glycoprotein 
and organic anion transporters (Bista et al., 2006, Lee and Stockley, 2003). Pharmacodynamics (what the drug does to the body) is 
related to the pharmacological activity of interacting drugs. The outcome is an amplification or decrease in the therapeutic effects 
or side-effects of a specific drug.  
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Figure 1. Chemical structures of hypericin and hyperforin, biologically active constituents of St John’swort. 
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Figure 2. Chemical structures of silybin, silychristin, silydianin, biologically active constituents of Milk thistle. 
 
 
 
Type of drug interactions (DIs): 
 
 Drug Interactions may be broadly classified as: 
 
I. Drug-disease interaction 
 
This type of drug interaction is associated in patients suffering from renal and hepatic impairment. Patient at high risk 
for drug-disease interactions include those suffering from aplastic anemia, asthma, cardiac arrhythmia, intensive care patients, 
diabetes, epilepsy and hypothyroidism. It is therefore essential to monitor the conditions and required doses of the drug to prevent 
serious repercussions (Lambrecht et al., 2000). 
 
II. Drug-herb interaction 
 
Several cases of possible herb drug interactions have been reported (Cupp et al., 1999). Herbal products can produce 
ADRs likely due to lack of standardization of content of natural products, variations in the strength of the active ingredient, 
contamination by fungal organisms and adulteration with other potentially harmful natural products (Chan et al., 1995). Some of 
the clinically significant drug-herb interactions reported or suspected is listed in the Table 1. And examples of herbal medicine 
involved in drug interaction and their possible mechanism of interaction with the source of evidence are listed in Table 2. 
 
III. Drug-drug interaction 
 
This type of interaction is associated with both prescriptions as well as over-the counter (OTC) drugs. For example; 
Antibiotic Ciprofloxacin taken with antacids lowers its effectiveness. Similarly, Digoxin and Amiodarone combination leads to 
increased Digoxin toxicity. Among the different types of DIs, the DDIs  are most common of their high incidence rate and the 
serious outcomes (Wijnands et al., 1987). 
. 
IV. Miscellaneous DIs 
 
This includes interaction of drug with dietary supplements, food and beverages, cigarettes etc. Component Vitamin K is 
present in many vegetables. It promotes production of blood-clotting factors that may reduce the effectiveness of anticoagulant 
drug like Warfarin. Many reports on reduction of the efficacy of Warfarin with intake of huge quantities of ice cream have been 
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reported (Leon et al., 1971). Vitamin B6 (Pyridoxine) found in avocados, beans, peas, sweet potatoes, bacon, beef liver, pork, tuna 
and vitamin-mineral products increases the metabolism of Levodopa, producing decreased blood levels of Dopamine and is 
associated with parkinsonism symptoms (Jusko et al., 1979). Concurrent use of Theophylline and tobacco may result in decreased 
theophylline concentration. Theophylline doses may need to be reduced by 25% to 33% after discontinuation of tobacco smoking. 
Monitoring of theophylline plasma concentrations may be necessary to optimize therapy (Kruth et al., 2004, Yue and Jansson, 
2001, Izzat et al., 1998, Tam et al., 1995, Jiang et al., 2004). 
 
Mechanism of herbal-drug interactions 
 
Herbal medicines follow modern pharmacological principles. Hence, Herb–drug interactions could be characterized 
either by pharmacokinetic (PK) or pharmacodynamic (PD) mechanisms. Pharmacokinetic interactions have been more 
extensively studied, and in-vitro and in-vivo studies indicate that the altered drug concentration by co-administered herbs may be 
attributed to the induction or inhibition of hepatic and intestinal drug-metabolizing enzymes, particularly Cytochrome P-450 
(CYP)], and/or drug transporters such as P-glycoprotein (Boullata et al., 2005, Hussain et al., 1999). The CYP is the most 
important Phase I drug-metabolizing enzyme system, responsible for the metabolism of a variety of drugs. Many herbs (e.g. St. 
John’s wort) and natural compounds isolated from herbs (e.g. flavonoids, coumarins, furanocoumarins, anthraquinones, caffeine 
and terpenes) have been identified as substrate inhibitors or inducers of various CYP enzymes (Dietary Supplement-A- 2005). 
Specifically, clinical studies have shown that long-term (2 weeks) administration of St. John’s wort significantly induced 
intestinal and hepatic CYP3A4 and possibly other CYP enzymes involved in drugs metabolism. Moreover, a clinical study 
performed on 12 healthy subjects showed that Echinacea modulated the catalytic activity of CYP3A at hepatic and intestinal sites 
(induction of hepatic CYP3A4 and inhibition of intestinal CYP3A4). In contrast, a number of herbal medicines including Green 
tea, Ginkgo garlic, and Saw palmetto and Siberian ginseng do not affect CYP3A4 and CYP2D6 activities in normal volunteers. P-
glycoprotein in the intestine, liver and kidney may play an important role in the absorption, distribution, or excretion of drugs. P-
glycoprotein appears to limit the cellular transport from intestinal lumen into epithelial cells and also enhances the excretion of 
drugs out via hepatocytes and renal tubules into the adjacent luminal space. Like CYP, P-glycoprotein is vulnerable to inhibition, 
activation, or induction by herbs and herbal constituents. Hyperforin, a major ingredient of St. John’s wort, binds to orphan 
pregnane X receptor, resulting in a series of intracellular events leading to the expression of CYP3A4 and P-glycoprotein. A few 
pharmacodynamic interactions have also been reported. Pharmacodynamic interactions may be additive (or synergetic), whereby 
the herbal drug potentiates the action of synthetic drugs (e.g. interaction between the anticoagulant warfarin with antiplatelet 
herb), or antagonistic, whereby the herbal medicine reduces the efficacy of synthetic drugs (e.g. kava possesses dopaminergic 
antagonistic properties and hence reduce the pharmacological activity of the anti-Parkinson drug levodopa) (Izzo et al., 2005). 
 
Determination of herbal-drug interactions  
Adverse event reporting (AER) 
 
Reports on adverse drug events are currently limited. The FDA maintains the Med Watch system for reporting adverse 
events, for both conventional drugs as well as dietary supplements. In 2002, 320860 adverse events were reported (Anon, 2002). 
However, the Med Watch system does not separate drug and herbal interactions. In addition, a report published by the Department 
of Health and Human Services (DHHS) estimated less than 1% of all drug–dietary supplement interactions to be reported to the 
FDA (Anon, 2001). A published review of widely claimed interactions found that <15% were well documented (Barnes et al., 
1998) The lack of available clinical data for many herbal products serves as a barrier for post marketing safety assessment of 
herbal products. 
 
Nature of herbal-drug interactions 
 
Unlike conventional drug, most of the natural products are complex mixture of chemical constituents, which may or 
may not show any therapeutic activity. Often complete characterization of all the chemical constituents in a natural product is 
unknown. Additionally, chemical makeup of a natural product may vary, depending on the part of the plant processed (roots, 
stems, leaves, fruits), season and growing conditions.  
Not only does the complex nature of natural products complicate the determination of drug–herbal interactions, but also 
the manufacturing procedures. Because herbal products are not regulated by the FDA, there are no standards for herbal products. 
Indeed, some products have been found to be misidentified, substituted and/or adulterated. Testing of the quality of more than 
1200 dietary supplement products by the independent laboratory ConsumerLab.com found that 1 in 4 dietary supplement 
products, lacked the labeled ingredients or had other serious problems such as unlisted ingredients or contaminants. This creates a 
problem while evaluating the validity of drug–herbal interactions (Rodriguez-Landa et al., 2003). Herbal products are not 
regulated for purity and potency like other pharmaceuticals [Dietary Supplement Health and Education Act of 1994, Public Law 
No. 103-417, 1994]. Thus, there are possibilities that the adverse effect and drug interaction of herbal products could be caused by 
impurities (e.g., allergens, pollens and spores), batch-to-batch variability. Medical practitioners must be aware of herb-drug 
interactions, in order to avert deadly risks for patients.  
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Table 1. Some clinically significant drug-herb interactions: 
 
Herbal drugs Biological source Interaction reported or suspected 
Ginkgo  Ginkgo biloba Concurrent use of ginkgo and nonsteroidal antiinflammatory 
agents may result in an increased risk of bleeding and with 
warfarin causes bleeding. (Meisel et al., 2003) 
Garlic  Allium sativum Concurrent use of garlic and anticoagulants result in increased 
risk of bleeding. (Legnani et al., 1993) 
Ginger Zingibar officinale Concurrent use of ginger and anticoagulants may result in 
increased risk of bleeding, sulfa guanidine enhance absorption. 
(Kruth et al., 2004) 
Ginseng  Panax ginseng Concurrent use of ginseng and antidiabetic agents may result in 
increased risk of hypoglycemia. (Vuksan et al., 2000) 
St. John’s wort Hypericum perforatum Concurrent use of digoxin and St John's wort may result in 
reduced digoxin efficacy. (Hennessy et al., 2003) 
St. John’s wort 
 
Hypericum perforatum Warfarin (cause bleeding); serotonin-uptake inhibitors (cause 
mild serotonin syndrome); indinavir (decreased 
bioavailability); digitoxin, theophylline, cyclosporin, 
phenprocoumon and oral contraceptives reduces 
bioavailability. (Cupp et al., 1999) 
Rhubarb Rheum officinale Cardiac glycosides and anti-arrhythmic agents potentiates by 
reducing potassium via laxative effect. (Westendorf, 1993) 
Astragalus Astragalus membranaceus Cyclosporine, azathioprine, methotrexate impair immuno-
suppressive effects. 
Licorice 
 
Glycyrrhiza uralensis Corticosteroids and thiazide diuretics potentiating; digitalis or 
other cardiac glycosides increases sensitivity (Mu et al.,2006) 
Ma-huang 
 
Ephedra sinica 
 
With MAO inhibitors cause hypertension; cardiac glycosides or 
halothane react to produce cardiac arrhythmia; caffeine 
intensify cardiovascular side effects. 
Aloe Aloe ferox Cardiac glycosides and antiarrhythmic agents potentiates by 
reducing potassium via laxative effect (Westendorf, 1993) 
Salvia Salvia miltiorrhiza With warfarin cause bleeding (Gaddis et al., 2002) 
Bupleurum Bupleurum falcatum With sedatives potentiating effect 
 
 
 
 
Patient counseling about herbal-drug interactions 
 
Use of herbal and dietary supplements is extremely common. In US survey, adults who regularly take prescription medication, 
18.4% of them reported the concurrent use of at least one herbal product or high-dose vitamin (and 61·5% of those who used 
unconventional therapies did not disclose such use to their physicians). A survey of 515 users of herbal remedies in the UK found 
that 26% would consult their general practitioner for a serious adverse drug reaction associated with a conventional over-the-
counter medicine, but not for a similar reaction to herbal remedy (Gorski et al., 2004). Clinicians must guide patients about use of 
herbs in a non-judgmental manner. The patient should be alerted for adverse reactions or interactions, and should be told about the 
proper use of herbal drugs (Mohammad et al., 2009). Formulation, brand, dose, and direction for use of herbs should be 
documented on the patient’s charts and updated regularly. Patients with clotting disorders, those awaiting surgery, or those on 
anticoagulant therapy should be warned against the concurrent use of ginkgo, danshen, dong quai, papaya, or garlic. Many other 
herbs also contain anticoagulant substances as a precaution; patients on warfarin should have an INR measurement within a week 
of starting any herbal treatment. Patients on serotonin-reuptake inhibitors, cyclosporin, digoxin, phenprocoumon, or any critical 
chronic medication should avoid St John’s wort; while those on phenelzine and tricyclic antidepressants should avoid ginseng and 
yohimbine respectively. There are still undoubtedly many undiscovered interactions 
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Table 2: Examples of herbal medicine involved in drug interaction and their possible mechanism of interaction: 
  
     Drug     Herb Result of 
interaction 
   Possible mechanism Source of 
evidence 
Reference  
 
Alprazolam 
 
 
 
St John’s wort 
 
 
 
Decreased plasma 
levels Alprazolam 
 
 
Alprazolam is a specific 
probe for CYP 3A4, 
which is induced by St 
John’s wort. 
Clinical 
studies 
 
 
 
Jiang et al., 
2004, Schmider 
et al ., 2002 
 
Amitriptyline 
 
 
 
 
St John’s wort 
 
 
 
 
 
Decreased plasma 
levels of the drug 
 
 
 
 
Amitriptyline is a 
substrate of both 
CYP2C19 and P-
glycoprotein which is 
induced by St John’s 
wort. 
 
A clinical 
study 
 
 
 
 
 
Dannawi et al., 
2002 
 
 
 
 
 
 
Buspirone 
 
 
 
St John’s wort 
 
 
Hypomania 
 
Synergistic effect on 5-
HT receptor. 
 
A case 
report 
 
Gorski et al. 
2004 
 
Aspirin 
 
Ginkgo 
 
Spontaneous 
hyphema 
 
Additive effect on 
platelet aggregation; 
ginkgolides show 
antiplatelet activity 
A case 
report 
 
Leon et al., 1971 
 
 
Lovastatin 
 
Pectin or oat 
bran 
 
Decreased 
absorption of 
Lovastatin 
 
Pectins or bran fibres 
may bind or trap 
lovastatin in the gut. 
 
A clinical 
study 
 
Jusko et al., 
1979 
 
Simvastatin 
 
St John’s wort 
 
Decreased Plasma 
Digoxin conc.             
 
Simvastatin is a substrate 
of P- glycoprotein and is 
metabolized by CYP 
enzymes. Both CYP 
enzymes and P-
glycoprotein are induced 
by St John’s wort 
A clinical 
study 
 
Kruth et al., 
2004 
 
 
 
 
 
 
Phenprocoumon 
 
Ginger 
 
 
 
St John’s wort 
 
(i) Over-
anticoagulation 
 
 
(ii) decreased 
anticoagulant effect 
 
(i) Additive effect on 
coagulation ( ginger 
inhibits platelet 
aggregation) 
(ii)Phenprocoumon is 
metabolized by 
cytochrome enzymes 
induced by St John’s 
wort. 
A case 
report 
 
 
A clinical 
study 
 
Yue and 
Jansson, 2001 
 
 
Izzat et al., 1998 
 
Verapamil 
 
St John’s wort 
 
Decreased 
bioavailability 
of verapamil 
 
Induction of intestinal 
CYP3A4 by St John’s 
wort. 
 
A clinical 
study 
 
Tam et al., 1995  
Digoxin 
 
Gum guar, 
St John’s 
wort, Wheat 
bran 
 
Decreased plasma 
Digoxin 
concentration 
 
 (i) Gum guar delays 
gastric emptying and 
hence may reduce 
digoxin absorption 
(ii) St John’s wort 
induces P-glycoprotein 
which is involved in 
digoxin absorption/ 
excretion 
(iii) Fibres in bran may 
trap digoxin in the gut. 
 
Clinical 
studies  
 
Lee and 
Stockley, 2003, 
Lambrecht et al., 
2000,  
Cupp et al., 
1999, Chan et 
al., 1995,  
 
 
Wijnands et al., 
1987 
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Warfarin Danshen Increase their risk 
for bleeding. 
Additive effect due to 
coumarin content in 
danshen 
Case report Chan et al., 
1995, Tam et al., 
1995, Yu et al., 
1997  
Warfarin Dong quai Increase their risk 
for bleeding. 
Possible inhibition of 
platelet activity by dong 
quai 
Case report Woo et al., 
1995, Lawrence 
et al., 1999 
Sodium valproate Ginkgo 
biloba 
Decreased   
bioavailability 
of valproate 
 
Contaminants of 
leaf/seed which may 
contain neurotoxins 
Case report Granger et al., 
2001, 
Bebbington et 
al., 2005, 
Mohutsky et al., 
2006  
 
 
.  
 
Drug interaction with herb 
 
When a drug is mixed with food or another herb, each can alter the way the body metabolizes the other. Some drugs 
interfere with the body's ability to absorb nutrients. Similarly, certain herbs and food can decrease or increase the impact of a 
drug.  
 
 Alcohol interacts with almost every medication, especially antidepressant and other drugs that affect the brain and nervous 
system. 
Some dietary components increase the risk of side effects. Theophylline, administered to treat asthma, contains xanthenes, which 
is also present in tea, coffee, chocolate and other sources of caffeine. Consuming large amount of such substances, with 
theophylline increases the risk of toxicity. 
 Dietary fiber affects drug absorption. Pectin and other soluble fibers slow down the absorption of acetaminophen, a popular 
painkiller. Bran and other insoluble fibers have a similar effect on digoxin, a major cardiac medication. 
With new herbs, there is increased potential for its abuse and the patients may end up with serious problems. High-risk patients, 
such as the elderly on multiple medications for chronic conditions, patients suffering from diabetes, hypertension, depression, 
high cholesterol or congestive heart failure should be alerted against such reactions. 
 
Examples of interaction among herb, food, prescription, non prescription/over the counter drugs: 
 
Hawthorn effective in reducing angina attack, by lowering blood pressure and cholesterol level, should never be taken along with 
Lanoxin (digoxin), commonly prescribed for cardiac ailments. The combination can lower heart rate, causing blood to pool, 
resulting in possible cardiac failure. 
 
Ginseng according to research could increase blood pressure, so is not advisable in patients with hypertension. Ginseng, garlic or 
supplements containing ginger, when taken with the blood-thinning drug Coumadin, could cause bleeding episodes. In some 
cases, ginseng may over stimulate and result in insomnia. Caffeine and ginseng combination increases the risk of overstimulation 
and gastrointestinal upset. Long term use of ginseng may cause menstrual abnormalities and breast tenderness in some women. 
Ginseng is not advisable for pregnant or lactating women. 
 
Garlic containing herbal capsules when combined with diabetes medication could cause dangerous decrease in blood sugar level. 
Some garlic sensitive individuals may experience heart burn and flatulence. Garlic has anti-clotting properties; one should consult 
the doctor before taking any anticoagulant drug. 
 
Goldenseal is often used for cough, stomach upset, arthritis and menstrual problem. However, this plant's active ingredients raises 
blood pressure, which could interfere with treatment of those on antihypertensive medication especially beta-blocker. This herb 
can also cause dangerous electrolyte imbalance in patients suffering from diabetes or kidney disorders. Consumption in heavy 
doses could lead to gastrointestinal distress and nervous system abnormalities. It is not recommended for pregnant and lactating 
women. 
 
Feverfew believed to be the natural remedy for migraine, should never be taken with Imitrex or other migraine medication. It 
could result in elevated blood pressures and heart-rate. 
 
Guarana an alternative remedy as stimulant and dietary aid, contains 3% to 5% more caffeine than that present in a cup of coffee. 
It may cause insomnia, trembling, anxiety, palpitations, urinary frequency and hyperactivity. It should be avoided during 
doi: 10.4314/ajtcam.v8i5S.8
Hussain Afr J Tradit Complement Altern Med. (2011) 8(S):152-163 160
pregnancy and lactation. Long term use of Guarana may lead to decreased fertility, cardiovascular disease and several forms of 
cancer. 
 
Kava has antianxiety, pain relieving, muscle relaxing and anticonvulsant effects. It should not be taken with central nervous 
system stimulants such as alcohol, barbiturates, antidepressants, and antipsychotic drugs. 
 
St. John's Wort is a popular herb for the treatment of mild depression. Its active ingredient hypericin is believed to exert similar 
effect on the brain as the monoamine oxidase (MAO) inhibitors. Taking MAO inhibitors with food rich in tyramine (an amino 
acid) produces dramatic food-drug interaction. Foods rich in tyramine include chicken liver, yeast extracts, dried or pickled fish, 
legumes, soy sauce and beer. Symptoms of such interaction include rapid rise in blood pressure, severe headache which may lead 
to even death. This herb in some patients caused excessive stimulation, dizziness and agitation with certain anti-depressants and 
OTC medication like Dexatrim and Acutrim. (Aga et al., 2003).  
 
Drug interaction with food 
 
Drug interaction risk is not limited to herbal supplements. People taking digoxin should avoid black licorice as it 
contains glycyrrhizin. Together they interact to produce irregular heart rhythms and cardiac arrest. Licorice and diuretics lower 
the potassium levels, cause numbness weakness, muscle pain and even paralysis. (Sorensen et al., 2002). 
 
Grapefruit juice interact with calcium channel blockers such as Calan, Procardia, Nifedipine, and Verapamil, anti-psychiatric 
medication, estrogen, oral contraceptive and certain anti-allergic drugs such as Seldane, Hismanal.  
 
Orange juice must not be consumed with antacids containing aluminum. The juice increases the absorption of aluminum and 
leads to severe constipation. Orange Juice and milk should be avoided with taking antibiotics, as they decrease its effectiveness. 
Milk contains elements like Mg and Ca which chetate antibiotics like tetracycline and hence decrease its absorption and effect. 
 
Milk does not mix with laxatives which contain bisacodyl (Correctol and Dulcolax). Large amount of oatmeal and other high-
fiber cereals should not be eaten with digoxin, as it interferes with drug absorption. A professional expert could recommend 
dietary changes after carefully examining the digoxin levels.  
 
Leafy green vegetables high in vitamin K content should not be consumed with Coumadin, as it  negates the effects of the drug 
and can lead to blood clotting. 
 
Caffeinated beverages and antiasthmatic drugs or quinolone antibiotics such as Cipro, penetrex, noroxin and oral contraceptives 
taken together can cause excessive excitability. (Shannon et al., 1997).             
 
Grilled meat can lead to severe problems for those on asthmatic medication containing theophylline as its interaction, increases 
the possibility of an unmanageable asthmatic attack. Regular consumption of diet rich in fat, with anti-inflammatory and anti-
arthritic drugs can cause kidney damage.  
 
Alcoholic beverages tend to increase the depressive effect of medications such as benzodiazepines, antihistamines, 
antidepressants, antipsychotics, muscle relaxants, narcotics, or any drug with sedative actions. Antioxidants and beta-carotene 
intensify the effect of alcohol on the liver. (Barone et al., 2001). 
 
Tomato contains small quantity of a toxic substance known as solanine that may trigger headache in certain individuals. An 
unidentified constituent in tomato and tomato-based products can cause acid reflux, leading to indigestion and heartburn. 
 
Strawberry, raspberry, spinach and rhubarb contain oxalic acid, which can aggravate kidney and bladder stones in susceptible 
individuals and reduce ability to absorb iron and calcium. Raspberries contain a natural salicylate which can cause allergic 
reaction in aspirin sensitive individuals. 
 
Potato especially the unripe and with a green tint in skin contain solanine, a toxic substance that can lead to diarrhea, cramps, and 
fatigue. 
 
Plums, peaches, apricots and cherries may produce allergic reaction in certain individuals, as it contains salicylates. The pits of 
plums, peaches and apricots contain a compound called amygdalin.  When consumed in large amounts, amygdalin breaks down to 
form hydrogen cyanide which causes poisoning. 
 
How to minimise drug interactions 
 
Some broad principles may help prescribers to minimize risk of drug interaction to the patients.  
 Beware with drugs with narrow therapeutic window e.g. anticoagulants, anticonvulsive drugs. 
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 Be aware with drugs which are enzyme inducers or inhibitors. 
 Consider drug pharmacology to avoid pharmacodynamic interaction with drugs, herbal and food supplements. 
 Avoid multiple drug combination (especially those involving NSAIDS) if risks outweigh the benefits. 
 High alert while prescribing for elderly or chronically ill patients. 
 
Limitations 
 
Much of the available information on interaction between herbal products and prescribed drugs is gleaned from case 
reports, although clinical studies are now also beginning to appear in the literature. The published case reports are often 
incomplete. According to the scoring system described by Fugh-Berman and Ernst (Fugh-Berman et al., 2001), 68.5% of the cases 
reported were classified as ‘invaluable’ as they contained inadequate information to assess the likelihood of an interaction, 18.5% 
were classified as ‘possible’ as they provided some evidence of interaction and 13% as ‘well documented’ when  they provided 
reliable evidence of interaction.  
 
Conclusion  
 
Contrary to popular belief that “natural drugs are safe”, herbal medicines can cause significant toxic effects, drug 
interaction and even incidences of morbidity or mortality. This article is not against herbal medicines. Based on evidence from in 
vitro, in vivo and clinical studies, herbal and other dietary supplements have shown interaction with many drugs. Still many drug-
herbal interactions are difficult to evaluate. Physicians must indulge in patient counseling to avoid risks of drug interaction with 
herbal supplements. The interaction often involves drug-metabolizing enzymes and drug transporter systems, besides 
pharmacodynamic interaction. Since the pharmacokinetic and pharmacodynamic characteristics of most herbal and other dietary 
supplements are not completely recognized, potential interactions are often not predictable. Potential interactions are likely to 
occur with drugs with narrow therapeutic index. The evidence based evaluation used in the study can be used to evaluate 
reliability of the case reports. 
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